Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants
| Autor: | James Balsley, Michael Boeckh, Lawrence Corey, M. Michelle Berrey, Stephen W. Crawford, Raleigh A. Bowden |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Palivizumab
Adult Male Adolescent medicine.medical_treatment Hematopoietic stem cell transplantation Respiratory Syncytial Virus Infections Antibodies Monoclonal Humanized Antiviral Agents Transplantation Autologous Disease Outbreaks chemistry.chemical_compound medicine Ethnicity Immunology and Allergy Humans Transplantation Homologous Child Bone Marrow Transplantation business.industry Ribavirin Respiratory disease Hematopoietic Stem Cell Transplantation Antibodies Monoclonal Infant Middle Aged medicine.disease United States Respiratory Syncytial Viruses Transplantation Pneumonia Infectious Diseases Upper respiratory tract infection chemistry Child Preschool Immunology Female Viral disease Drug Monitoring Safety business medicine.drug |
| Zdroj: | The Journal of infectious diseases. 184(3) |
| ISSN: | 0022-1899 |
| Popis: | Intravenous palivizumab (15 mg/kg) was investigated in 2 phase 1 studies among recipients of hematopoietic stem cell transplants (HSCTs). Study 1 included 6 HSCT patients without active respiratory syncytial virus (RSV) infection. Study 2 included 15 HSCT patients with RSV upper respiratory tract infection (URTI; n=3) or RSV interstitial pneumonia (IP; n=12), all of whom also received aerosolized ribavirin. Peak serum concentrations of palivizumab in the 2 studies were similar. The mean serum half-life was 22.4 days in study 1, which mainly included autologous HSCT recipients, and 10.7 days in study 2, which mainly included allogeneic HSCT recipients. No antibodies to palivizumab were detected in study 1. No adverse events were attributed to palivizumab in the 2 studies. In study 2, all 3 patients with RSV URTI recovered without progression to lower respiratory tract disease, and 10 (83%) of the 12 patients with RSV IP survived the 28-day study period. Thus, palivizumab appears to be safe and well tolerated in HSCT recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|